Amna Nawaz:

Judy, one of the most debated pieces of the bill is an agreement that would allow the government through Medicare to negotiate prices with pharmaceutical companies on certain drugs starting in 2025.

It would also cap out-of-pocket costs for seniors at $2,000 a year, starting in 2024. For diabetic patients, out-of-pocket costs for insulin would be capped at $35 for a 30-day supply That’s starting in 2023.

To help us understand more about the impact of this and its limits, I’m joined by Stacie Dusetzina, associate professor of health policy at Vanderbilt University School of Medicine.

Professor, welcome to the “NewsHour.” Thank you for making the time.

That key provision in this proposal, the ability to negotiate for prescription drug prices, we know some Democrats wanted Medicare to have the power to do that with many more drugs, up to 250 drugs. That was significantly scaled back in this bill.

Tell me about that and the impact you through that will have.